Having trouble accessing articles? Reset your cache.

Assays and screens

TECHNOLOGY: Bioinformatic screens; cell-free assays

A low-cost computational method for quantifying tumor cfDNA could identify cancer patients eligible for high-cost, whole-exome sequencing-based personalized medicine. The method

Read the full 252 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE